Equities research analysts predict that Envision Healthcare Co. (NYSE:EVHC) will announce sales of $1.98 billion for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Envision Healthcare’s earnings. The lowest sales estimate is $1.94 billion and the highest is $2.00 billion. Envision Healthcare reported sales of $1.39 billion in the same quarter last year, which would suggest a positive year over year growth rate of 42.4%. The firm is expected to report its next earnings results on Tuesday, February 27th.

On average, analysts expect that Envision Healthcare will report full year sales of $1.98 billion for the current fiscal year, with estimates ranging from $7.76 billion to $7.88 billion. For the next year, analysts anticipate that the company will report sales of $8.39 billion per share, with estimates ranging from $8.11 billion to $8.78 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Envision Healthcare.

Envision Healthcare (NYSE:EVHC) last issued its quarterly earnings data on Tuesday, October 31st. The company reported $0.73 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.81 by ($0.08). The business had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $2.03 billion. Envision Healthcare had a positive return on equity of 4.88% and a negative net margin of 6.39%. The company’s revenue for the quarter was up 142.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.13 earnings per share.

A number of brokerages recently issued reports on EVHC. Zacks Investment Research upgraded shares of Envision Healthcare from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Mizuho decreased their price objective on shares of Envision Healthcare from $65.00 to $57.00 and set a “neutral” rating for the company in a report on Wednesday, August 9th. Robert W. Baird decreased their price objective on shares of Envision Healthcare from $70.00 to $35.00 and set an “outperform” rating for the company in a report on Friday, November 3rd. BidaskClub cut shares of Envision Healthcare from a “sell” rating to a “strong sell” rating in a report on Thursday, August 17th. Finally, Oppenheimer decreased their price target on shares of Envision Healthcare from $77.00 to $40.00 and set an “outperform” rating for the company in a report on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, six have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $47.57.

Several institutional investors and hedge funds have recently made changes to their positions in the company. ING Groep NV raised its position in shares of Envision Healthcare by 0.3% during the second quarter. ING Groep NV now owns 6,022 shares of the company’s stock valued at $377,000 after buying an additional 21 shares during the last quarter. CIBC Asset Management Inc raised its position in shares of Envision Healthcare by 0.4% during the second quarter. CIBC Asset Management Inc now owns 10,078 shares of the company’s stock valued at $632,000 after buying an additional 38 shares during the last quarter. Sawtooth Solutions LLC raised its position in shares of Envision Healthcare by 0.7% during the second quarter. Sawtooth Solutions LLC now owns 6,656 shares of the company’s stock valued at $417,000 after buying an additional 43 shares during the last quarter. Boys Arnold & Co. Inc. raised its position in shares of Envision Healthcare by 0.6% during the second quarter. Boys Arnold & Co. Inc. now owns 8,125 shares of the company’s stock valued at $509,000 after buying an additional 50 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Envision Healthcare by 1.5% in the second quarter. PNC Financial Services Group Inc. now owns 4,848 shares of the company’s stock worth $304,000 after purchasing an additional 70 shares in the last quarter.

Shares of Envision Healthcare (EVHC) traded down $0.70 during trading hours on Thursday, reaching $30.53. 2,997,900 shares of the company were exchanged, compared to its average volume of 2,240,726. The company has a market capitalization of $3,775.37, a PE ratio of 9.64, a PEG ratio of 0.81 and a beta of 0.57. Envision Healthcare has a 12-month low of $23.77 and a 12-month high of $73.72. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.01 and a quick ratio of 3.00.

Envision Healthcare declared that its Board of Directors has approved a share buyback plan on Monday, September 18th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to reacquire up to 4.5% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: This report was first reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/07/zacks-analysts-expect-envision-healthcare-co-evhc-will-post-quarterly-sales-of-1-98-billion.html.

Envision Healthcare Company Profile

Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.

Get a free copy of the Zacks research report on Envision Healthcare (EVHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Envision Healthcare Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare Co. and related companies with MarketBeat.com's FREE daily email newsletter.